Corrigendum to "Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center" [Gynecol. Oncol. 142 (2016) 13-18]. Academic Article